Witnessing the stock’s movement on the chart, on Wednesday, Fate Therapeutics Inc (NASDAQ: FATE) set off with pace as it heaved 9.90% to $1.11, before settling in for the price of $1.01 at the close. Taking a more long-term approach, FATE posted a 52-week range of $0.66-$1.94.
The Healthcare Sector giants’ yearly sales growth during the last 5-year period was -2.63%. Meanwhile, its Annual Earning per share during the time was -2.63%. Nevertheless, stock’s Earnings Per Share (EPS) this year is 29.82%. This publicly-traded company’s shares outstanding now amounts to $115.34 million, simultaneously with a float of $109.75 million. The organization now has a market capitalization sitting at $128.05 million. At the time of writing, stock’s 50-day Moving Average stood at $1.0914, while the 200-day Moving Average is $1.1362.
Fate Therapeutics Inc (FATE) Ownership Facts and Figures
Nothing is more important than checking the behaviour of major investors towards the stock of the Biotechnology industry. Fate Therapeutics Inc’s current insider ownership accounts for 4.91%, in contrast to 71.32% institutional ownership. Preceding that transaction, on Aug 04 ’25, Company’s insider sold 9,037 for 1.06, making the whole transaction’s value amount to 9,573. This particular insider is now the holder of 397,670 in total.
Fate Therapeutics Inc (FATE) Earnings and Revenue Records
Fate Therapeutics Inc’s EPS increase for this current 12-month fiscal period is 29.82% and is forecasted to reach -1.16 in the upcoming year. Considering the longer run, market analysts have predicted that Company’s EPS will increase by 11.87% through the next 5 years, which can be compared against the -2.63% growth it accomplished over the previous five years trading on the market.
Fate Therapeutics Inc (NASDAQ: FATE) Trading Performance Indicators
Let’s observe the current performance indicators for Fate Therapeutics Inc (FATE). It’s Quick Ratio in the last reported quarter now stands at 7.87. Another valuable indicator worth pondering is a publicly-traded company’s price to sales ratio for trailing twelve months, which is currently 17.93.
In the same vein, FATE’s Diluted EPS (Earnings per Share) trailing twelve months is recorded -1.32, a figure that is expected to reach -0.27 in the next quarter, and analysts are predicting that it will be -1.16 at the market close of one year from today.
Technical Analysis of Fate Therapeutics Inc (FATE)
Going through the that latest performance of [Fate Therapeutics Inc, FATE]. Its last 5-days volume of 1.59 million was inferior to the volume of 1.79 million it revealed a year ago. During the previous 9 days, stock’s Stochastic %D was recorded 59.52% While, its Average True Range was 67.55.
Raw Stochastic average of Fate Therapeutics Inc (FATE) in the period of the previous 100 days is set at 17.54%, which indicates a major fall in contrast to 88.83% during the last 2-weeks. If we go through the volatility metrics of the stock, In the past 14-days, Company’s historic volatility was 0.0586 that was lower than 0.0988 volatility it exhibited in the past 100-days period.
